Uganda: HIV-Aids - Focus On Vulnerable Groups

[Monitor] Sometimes, it feels like the fight against HIV/Aids will never end. Each year, a report is released; it might be one showing what new trends are among those infected, or one stating the new challenges pharmacists are meeting in the struggle to come up with a vaccine. What must be applauded is the determination of those involved to find a cure and a way to reduce the risk people are exposed to. What must be acknowledged though is that there are still many hurdles to jump in the fight.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

As the AIDS epidemic unfolded, the appearance of opportunistic infections in at-risk persons provided clues to the underlying problem: a dramatic defect in cell-mediated immunity associated with infection and depletion of CD4+ T lymphocytes. Moreover, the emergence of HIV-associated malignancies in these same individuals was a clear indication of the significant role effective cellular immunity plays in combating cancers. As research in the HIV field progressed, advances included the first demonstration of the role of PD-1 in human T cell exhaustion, and the development of gene-modified T cell therapies, including chimeric...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
No abstract available
Source: AIDS - Category: Infectious Diseases Tags: Errata Source Type: research
Abstract Thailand has the highest prevalence of HIV among countries in Asia but has also been a pioneer in HIV prevention and treatment efforts in the region, reducing the incidence of new infections significantly over the last two decades. Building upon this remarkable history, Thailand has set an ambitious goal to stop the AIDS epidemic in the country by 2030. A key component of the strategy to achieve this goal includes scale-up of HIV screening programs to facilitate early HIV diagnosis and investment in mechanisms to support immediate initiation of antiretroviral therapy (ART). Initiation of ART during early ...
Source: AIDS Research and Therapy - Category: Infectious Diseases Authors: Tags: AIDS Res Ther Source Type: research
es SL, Wejse C Abstract Two HIV virus types exist: HIV-1 is pandemic and aggressive, whereas HIV-2 is confined mainly to West Africa and less pathogenic. Despite the fact that it has been almost 40 years since the discovery of AIDS, there is still no cure or vaccine against HIV. Consequently, the concepts of functional vaccines and cures that aim to limit HIV disease progression and spread by persistent control of viral replication without life-long treatment have been suggested as more feasible options to control the HIV pandemic. To identify virus-host mechanisms that could be targeted for functional cure d...
Source: AIDS Research and Therapy - Category: Infectious Diseases Authors: Tags: AIDS Res Ther Source Type: research
CONCLUSIONS: RC remains a frequent argument against the availability and provision of prevention methods for vulnerable populations. Individuals should be able to benefit from the full panel of BIs options available, to find and adapt methods according to their needs. Current, past and future PrEP users, with other stakeholders, may provide valuable insight into innovative solutions and programmes to control HIV and other STIs. PMID: 31468693 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
CONCLUSIONS: A tailored practice improvement plan can be envisioned to achieve an optimally functioning STI care continuum. PMID: 31468743 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
AbstractPurpose of ReviewPersons with HIV are at a higher risk for acquiring HBV (hepatitis B virus) than the general population due to shared modes of transmission and are significantly more likely to develop and die from sequelae of chronic HBV infection. Early vaccination is key to achieving HBV protective immunity, but response rates are still much lower than in the general population, ranging from 35 to 70%. Individuals with HIV also experience more rapidly waning immunity than those without HIV. Strategies to augment initial response and improve long-term immunity in individuals with HIV include alterations in dose, ...
Source: Current HIV/AIDS Reports - Category: Infectious Diseases Source Type: research
Condition:   HIV Infections Interventions:   Biological: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48);   Biological: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48);   Biological: Vaccine Group C: Saline placebo (weeks 0,4,24,48);   Drug: Control PrEP:TDF /FTC once daily (weeks 0-26);   Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26) Sponsors:   MRC/UVRI Uganda Research Unit on Aids;   Imperial College London;   University College, Londo...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
[New Times] Global experts are going to share research on HIV vaccines and cures in a meeting that will bring together over ten thousand delegates in Kigali in December.
Source: AllAfrica News: HIV-Aids and STDs - Category: Infectious Diseases Source Type: news
Condition:   HIV Infections Interventions:   Biological: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48);   Biological: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48);   Biological: Vaccine Group C: Saline placebo (weeks 0,4,24,48);   Drug: Control PrEP:TDF /FTC once daily (weeks 0-26);   Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26) Sponsors:   MRC/UVRI Uganda Research Unit on Aids;   Imperial College London;   University College, Londo...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | AIDS Vaccine | Health | HIV AIDS | Vaccines